Manage settings
MENU
About this site
In het Nederlands
Home
Researchers
Projects
Organisations
Publications
Contact
Research Explorer
Your browser does not support JavaScript or JavaScript is not enabled. Without JavaScript some functions of this webapplication may be disabled or cause error messages. To enable JavaScript, please consult the manual of your browser or contact your system administrator.
Researcher
Vibeke Kruse
Profile
Projects
Publications
Activities
27
Results
2022
Biomarkers in immuno-oncology : from melanoma to other cancer types, from tissue to liquid biopsy, from late stage to early stage disease
Annabel Meireson
Lieve Brochez
Liesbeth Ferdinande
Vibeke Kruse
Dissertation
2022
Mental Health and Quality of Life among Patients with Cancer during the SARS-CoV-2 Pandemic: Results from the Longitudinal ONCOVID Survey Study
Emiel De Jaeghere
Heini Kanervo
Roos Colman
Wim Schrauwen
Nora Sundahl
Katrien Vandecasteele
Eline Naert
Lore Lapeire
Vibeke Kruse
Sylvie Rottey
Gilbert Lemmens
Hannelore Denys
U
Journal Article
in
Cancers
2022
2021
Checkpoint inhibition in combination with an immunoboost of external beam radiotherapy in solid tumors (CHEERS) : study protocol for a phase 2, open-label, randomized controlled trial
Mathieu Spaas
Nora Sundahl
Eva Hulstaert
Vibeke Kruse
Sylvie Rottey
Daan De Maeseneer
Veerle Surmont
Annabel Meireson
Lieve Brochez
Dries Reynders
Els Goetghebeur
Pieter Mestdagh
Piet Ost
A1
Journal Article
in
BMC CANCER
2021
Immune monitoring in melanoma and urothelial cancer patients treated with anti-PD-1 immunotherapy and SBRT discloses tumor specific immune signatures
Annabel Meireson
Simon Tavernier
Sofie Van Gassen
Nora Sundahl
Annelies Demeyer
Mathieu Spaas
Vibeke Kruse
Liesbeth Ferdinande
Jo Van Dorpe
Filomeen Haerynck
Karel Decaestecker
Sylvie Rottey
Yvan Saeys
Piet Ost
Lieve Brochez
A1
Journal Article
in
CANCERS
2021
Managing viral hepatitis in cancer patients under immune checkpoint inhibitors : should we take the risk?
Stijn De Keukeleire
Tijl Vermassen
Zahra Mosala Nezhad
Tessa Kerre
Vibeke Kruse
Hans Van Vlierberghe
Karim Vermaelen
Sylvie Rottey
A1
Journal Article
in
IMMUNOTHERAPY
2021
Selective oral MEK1/2 inhibitor pimasertib : a phase I trial in patients with advanced solid tumors
Sylvie Rottey
Vibeke Kruse
A1
Journal Article
in
TARGETED ONCOLOGY
2021
Selective oral MEK1/2 inhibitor pimasertib in metastatic melanoma : antitumor activity in a phase I, dose-escalation trial
Sylvie Rottey
Vibeke Kruse
A1
Journal Article
in
TARGETED ONCOLOGY
2021
Spatiotemporal evolution of radiation myositis on 18F-FDG PET/CT following hypofractionated radiotherapy of intramuscular melanoma metastases
David Creytens
Vibeke Kruse
Piet Ost
Editorial material
2021
2020
A randomized controlled phase II clinical trial on mRNA electroporated autologous monocyte-derived dendritic cells (TriMixDC-MEL) as adjuvant treatment for stage III/IV melanoma patients who are disease-free following the resection of macrometastases
Vibeke Kruse
Lieve Brochez
A1
Journal Article
in
CANCER IMMUNOLOGY IMMUNOTHERAPY
2020
Recommendations for skin cancer consultation and surgery during COVID‐19 pandemic
Lieve Brochez
Vibeke Kruse
Editorial material
2020
2019
Boosting anticancer immunity with radiotherapy
Nora Sundahl
Piet Ost
Vibeke Kruse
Karel Decaestecker
Dissertation
2019
Phase 2 trial of nivolumab combined with stereotactic body radiation therapy in patients with metastatic or locally advanced inoperable melanoma
Nora Sundahl
Jo Van Dorpe
Annabel Meireson
Lieve Brochez
Vibeke Kruse
Piet Ost
A1
Journal Article
in
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
2019
Throughput efficiency and service quality after process redesign at a cancer day care unit: Two sides of the coin?
Kaat De Pourcq
Paul Gemmel
Jeroen Trybou
Vibeke Kruse
A1
Journal Article
in
EUROPEAN JOURNAL OF CANCER CARE
2019
To treat or not to treat? Managing comorbidities in cancer patients under immune checkpoint inhibition
Stijn De Keukeleire
Tijl Vermassen
Vibeke Kruse
Karim Vermaelen
Sylvie Rottey
A1
Journal Article
in
ACTA CLINICA BELGICA
2019
2018
Challenging PD-L1 expressing cytotoxic T cells as a predictor for response to immunotherapy in melanoma
Lieve Brochez
Annabel Meireson
Ines Chevolet
Nora Sundahl
Piet Ost
Vibeke Kruse
A1
Journal Article
in
NATURE COMMUNICATIONS
2018
Endothelial indoleamine 2,3-dioxygenase is correlated with microsatellite status in colorectal carcinoma and predicts worse prognosis
Annabel Meireson
Ines Chevolet
Eva Hulstaert
Liesbeth Ferdinande
Piet Ost
Karen Geboes
Vibeke Kruse
Lieve Brochez
C3
Conference
2018
Peritumoral endothelial indoleamine 2,3-dioxygenase expression is an early independent marker of disease relapse in colorectal cancer and is influenced by DNA mismatch repair profile
Annabel Meireson
Ines Chevolet
Eva Hulstaert
Liesbeth Ferdinande
Piet Ost
Karen Geboes
Marc De Man
Dirk Van de Putte
Vibeke Kruse
Lieve Brochez
A2
Journal Article
in
ONCOTARGET
2018
Phase 1 dose escalation trial of ipilimumab and stereotactic body radiation therapy in metastatic melanoma
Nora Sundahl
Katrien De Wolf
Vibeke Kruse
Annabel Meireson
Dries Reynders
Els Goetghebeur
Mireille Van Gele
Reinhart Speeckaert
Lieve Brochez
Piet Ost
A1
Journal Article
in
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
2018
Psoriasis vulgaris exacerbation during treatment with a PD-1 checkpoint inhibitor : case report and literature review
Eva Hulstaert
Vibeke Kruse
Lieve Brochez
A2
Journal Article
in
CASE REPORTS IN DERMATOLOGY
2018
The impact of logarithmic dose banding of anticancer drugs on pharmacy compounding efficiency at Ghent University Hospital
Barbara Claus
Kaat De Pourcq
Vibeke Kruse
Paul Gemmel
Johan Vandenbroucke
A1
Journal Article
in
EUROPEAN JOURNAL OF HOSPITAL PHARMACY-SCIENCE AND PRACTICE
2018
2017
Bijwerkingen van 'immune checkpoint' inhibitoren : waar dient een huisarts alert op te zijn?
Tessa Kerre
Piet Ost
Barbara De Moerloose
Karim Vermaelen
Lieve Brochez
Vibeke Kruse
A2
Journal Article
in
TIJDSCHRIFT VOOR GENEESKUNDE
2017
Cost-effectiveness and budget effect analysis of a population-based skin cancer screening
Lore Pil
Isabelle Hoorens
Katrien Vossaert
Vibeke Kruse
Lieven Annemans
Lieve Brochez
A1
Journal Article
in
JAMA DERMATOLOGY
2017
The ION-Ghent guidelines for the management of immune related adverse events (irAE's)
Vibeke Kruse
Max Schreuer
Karim Vermaelen
Piet Ost
Tessa Kerre
Barbara De Moerloose
Lieve Brochez
A2
Journal Article
in
BELGIAN JOURNAL OF MEDICAL ONCOLOGY
2017
The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy
Lieve Brochez
Ines Chevolet
Vibeke Kruse
A1
Journal Article
in
EUROPEAN JOURNAL OF CANCER
2017
2016
Successful strategy to treat a solitary cystic melanoma brain metastasis
Vibeke Kruse
Tom Boterberg
Marjan Acou
David Creytens
Lieve Brochez
Giorgio Hallaert
A1
Journal Article
in
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
2016
Virale oncogenese van het merkelcelcarcinoom
Eva Hulstaert
Ines Chevolet
Vibeke Kruse
Lieve Brochez
A2
Journal Article
in
TIJDSCHRIFT VOOR GENEESKUNDE
2016
2015
Systemic immune changes associated with adjuvant interferon-α2b-therapy in stage III melanoma patients: failure at the effector phase?
Ines Chevolet
Max Schreuer
Reinhart Speeckaert
Isabelle Hoorens
Nanja van Geel
Vibeke Kruse
Mireille Van Gele
Lieve Brochez
A1
Journal Article
in
MELANOMA RESEARCH
2015